Pre-filled plasma half-life model for GHRP-2. See how a 15 minutes half-life affects steady state, accumulation, peak-trough swing, and clearance timing.
Preset values: 100 mcg every 8 hours, half-life ~15 minutes.
15 min half-life. Multi-dose daily protocols (pre-meal) aim to mimic ghrelin pulses.
Open interactive chart →The half-life used here (15 minutes) is the published or well-established estimate for GHRP-2 from pharmacokinetic studies. The default dose (100 mcg) and cadence (every 8 hours) reflect typical standard protocols — not a prescription or recommendation. Your specific product's label and your clinician's protocol override any default here.
Accumulation. With a half-life of 15 minutes and dosing every 8 hours, the ratio τ/t½ = 32.00 gives an accumulation factor of ~1.00×. That means the steady-state peak plasma mass is about 1.0× the mass of a single dose.
Time to steady state. Approximately 5 half-lives (~0.1 days) of consistent dosing before average concentration stops rising. Dose-escalation protocols that change doses before this point are titrating against a still-rising baseline, which is one reason weekly peptides feel "slow" at the start.
After a single dose, half of the GHRP-2 is gone in about 15 minutes, 97% is cleared in about 1.3 hours (five half-lives), and under 1% remains after about 1.7 hours.
| Cleared | Remaining | Half-lives | Time after one GHRP-2 dose |
|---|---|---|---|
| 50% | 50% | 1 | 15 minutes |
| 75% | 25% | 2 | 30 minutes |
| 90% | 10% | 3.3 | 50 minutes |
| 97% | 3% | 5.1 | 1.3 hours |
| 99% | 1% | 6.6 | 1.7 hours |
Between doses. At every 8 hours, doses land 32.00 half-lives apart, so about <0.1% of the peak is still present when the next dose goes in. The steady-state swing in this model runs from ~100 mcg at peak to ~<0.1 mcg at trough — a pulse that mostly clears before the next injection, so GHRP-2 does not build up much at this cadence.
A first-order, one-compartment model: it leaves out absorption delay from the injection depot, protein binding and individual differences in clearance, and effects can outlast plasma levels. Good for dosing rhythm; not clinical pharmacokinetics.
This chart uses an estimated GHRP-2 plasma half-life of about 15 minutes. Published values can vary by formulation, route, assay, and study design.
A simple first-order model reaches practical steady state after about five half-lives, which is roughly 1 hours for GHRP-2.
After a single dose, half of the GHRP-2 is gone in about 15 minutes, 97% is cleared in about 1.3 hours (five half-lives), and under 1% remains after about 1.7 hours. Those are plasma estimates from a half-life of 15 minutes; effects can outlast plasma levels, and detection windows depend on the assay.
Dosing every 8 hours is 32.00 half-lives apart, so about <0.1% of the peak level remains at the next dose. At steady state that means a peak of ~100 mcg and a trough of ~<0.1 mcg in the model.
No. It visualizes half-life, accumulation, peaks, and troughs from values you enter. It is not a prescription, dose recommendation, or substitute for the product label or clinician guidance.
Steady state explains why long-half-life compounds can keep rising for weeks after starting or changing a dose, while short-half-life compounds behave more like brief pulses.
Half-life charts for related peptides: GHRP-6 (30 minutes), Sermorelin (12 minutes), CJC-1295 (8 days), Hexarelin (1 hour).
Peptide Protocol logs every actual injection time and shows your real timeline — not a model. Side-effect tracking included.
Get the iPhone app →Educational use only. Nothing on this page constitutes medical advice. Pharmacokinetic parameters are published estimates; individual PK varies. Use label values and consult a clinician for any dosing decision.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.